Tyler Garman, MD

Garman is a urology resident at Johns Hopkins University in Baltimore, Maryland.

Articles by Tyler Garman, MD

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

July 21st 2026

Tyler S. Garman, MD, highlights phase 2 data on intravesical gemcitabine and docetaxel as first-line treatment of BCG‒naïve NMIBC.

Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com

Molecular imaging of the solid renal mass: What does the future look like?

ByTyler Garman, MD,Jack Campbell, MD,Mohammad Allaf, MD

March 13th 2026

"Emerging evidence indicates that molecular imaging may enable more accurate detection of primary RCC, improve surveillance for recurrence, and enhance identification of metastatic lesions compared with conventional imaging," write the authors.

Tyler Garman, MD

Articles by Tyler Garman, MD

Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC

Molecular imaging of the solid renal mass: What does the future look like?

Latest Updated Articles

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Individualizing androgen pathway therapy in mCSPC

Testosterone deficiency: FAQs from the AUA guideline

Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer

Matthew Galsky, MD, on how EV/pembrolizumab is redefining the MIBC treatment paradigm